Explore the Agenda
7:30 am Registration & Morning Coffee
Expanding Cell Therapy Impact in Europe through Smarter Investment Strategies, Innovative Science, & Patient-Centric Access Models
8:30 am Industry Leaders Fireside Chat: Navigating Europe’s Cell Therapy Landscape Amid Investment Pressures, Novel Approaches, & Opportunities for Patient Access
- Discuss how investment headwinds are shaping company strategies and what it takes to sustain progress in Europe
- Highlight the most promising scientific advances, including novel indications, armouring strategies, and in-vivo approaches
- Explore how patient access models, from point-of-care manufacturing to evolving reimbursement pathways, can unlock future growth
9:30 am Unlocking the Potential of 3rd Generation CARs with Dual Co-Stimulation
- Showcase the unique design of the only 3rd generation CAR with CD19 targeting plus CD28 and CD137 co-stimulatory domains
- Discuss clinical insights on safety and efficacy
New Data
10:00 am Evaluating Long-Term Outcomes of Approved CAR-T Therapies in Real- World Settings & Highlighting Upcoming CAR-T Therapies
- Share results from a multicentre Phase 2 trial in adult B-ALL, marking the first centralised EMA commercialisation request for a CAR-T product
- Compare real-world evidence of approved CAR-T and off-label B-cell lymphoma treatments to assess long-term efficacy and safety
- Discuss insights from Hospital Clinic Barcelona’s experience as one of Europe’s earliest CAR-T/TCR treatment centres
New Data
10:30 am Morning Break & Speed Networking
R&D Track
Innovation in Science
Highlighting CAR-NK & CAR-Treg Approaches as Versatile, Scalable & Safe Approaches
11:30 am Advancing Second-Generation Off-the-Shelf CAR-NK Therapies for Safer, More Scalable Cancer Treatment
- Explore how CAR-engineered NK cells enhance tumour targeting, persistence, and safety
- Discuss how these next-generation, allogeneic NK products improve manufacturability, cost efficiency, and clinical accessibility
New Data
12:00 pm Session Reserved for Miltenyi
12:30 pm Advancing Next-Generation NK Platforms through Antibody-Guided CAR-like NK Cells
- Showcasing a CAR-like NK platform that achieves targeted cytotoxicity via monoclonal antibody attachment, eliminating the need for genetic modification
- Presenting preclinical data validating the platform’s potent CD16-mediated activity
New Data
Manufacturing Track
Realising Scale & Access
Track Chair:
Enhancing Cell Therapy Production with Advanced Platforms & Automation
11:30 am Scaling Manufacturing of CAR-Neutrophils to Enhance Persistence & Overcome Exhaustion
- Explore scalable processes for producing CAR-engineered neutrophils with consistent quality and functionality
- Discuss how optimised culture and differentiation conditions prevent exhaustion and extend therapeutic lifespan
- Highlight how CAR-neutrophil manufacturing can enable durable, off-the-shelf solutions for solid tumour treatment
12:00 pm Session Reserved for Minaris
12:30 pm Exploring Automation to Scale Out Autologous CAR-T Manufacturing
- Examine how automation enables scalable, parallelised production of autologous CAR-T therapies without compromising quality
- Discuss how streamlined, modular manufacturing platforms can lower costs and accelerate patient access
1:00 pm Lunch & Networking Break
2:00 pm Uncovering the Potential of CD19 CAR-Tregs: Pre- Clinical Data Driving the Next Wave of Treg Therapies
- Evaluate CD19 CAR-Treg design, function, and in preliminary data
- Understand how pre-clinical results inform translational and clinical readiness
New Data
2:30 pm Session Reserved for Nona Bio
Developing Cutting Edge Tools to Discover Novel Targets & Receptor Constructs to Broaden Therapeutic Reach
2:40 pm Panel Discussion: Leveraging AI & Machine Learning to Accelerate R&D & Construct Design
- Explore how AI-driven tools are being applied to design next- generation receptor constructs with improved precision and functionality
- Discuss the use of machine learning in identifying novel targets and accelerating preclinical discovery
- Highlight the challenges of obtaining sufficient, high-quality datasets
Enabling Local Manufacturing to Accelerate Patient Access & Streamline CGT Site Operations
2:00 pm Panel Discussion: Feasibility & Merits of Setting up Point of Care Manufacturing to Drive Patient Access & Reduce CGT Costs
- Evaluating the true feasibility and practicality of point-of-care manufacturing in today’s CGT landscape
- Weigh upfront costs, staffing, and infrastructure requirements against potential long-term savings
- Discussing whether the benefits of local access outweigh regulatory, operational, and scalability hurdles
2:40 pm Academic Case Study: Key Steps to Achieve a GMPGrade Cell Therapy Facility
- Lessons learned from overcoming resource constraints, timelines, and regulatory inspections in an academic environment
- Planning and designing an academic GMP facility with the right infrastructure, cleanroom classifications, and compliance standards
3:10 pm Afternoon Break & Poster Session
Clinical Data Showcase: Demonstrating Breakthroughs with Clinical Data to Validate Innovation
4:00 pm Advancing CAR-T Therapies with Real-World Clinical Data to Drive Next- Generation Development
- Share up-to-date clinical data from the ongoing CAR-T program in T-cell leukaemia
- Discuss the latest development from OneChain’s next-generation CAR-T products across hematologic malignancies and solid tumours
- Explore advantages and opportunities with OneChain’s allogeneic iPSC-derived gamma delta T-cell platform
New Data
4:30 pm Overcoming Barriers to Homegrown CAR-TCR Development in Low & Middle Income Countries (LMICs)
- Examine key challenges in developing CAR-TCR therapies from bench to bedside in low- and middle-income countries, from infrastructure to funding gaps
- Share practical solutions to reduce costs, strengthen local manufacturing capacity, and accelerate clinical translation
- Present clinical data showcasing progress and potential for scalable, sustainable innovation in LMIC settings
5:00 pm Use of Quantum Engine to Develop Multiplex Dual-Targeting CD19/CD20 CAR-T (SCM) Therapy for B-Cell Malignancies
- Introduce Quantum Engine for non-viral gene therapy
- Describe the benefits of dual-targeting CD19/CD20 T(SCM) cells to overcome antigen escape and improve response durability
- Present preliminary findings from a Phase I open-label trial of GF-CART01 for relapsed or refractory B-cell haematologic cancers
New Data